FLT3 and acute myeloid leukemia: Within the last years, a lot of new therapeutics targeting AML-associated molecular aberrations such as mutated IDH1 [107], IDH2 [108], FLT3-ITD [109] and/or FLT3-TKD [110], surface antigens [111], or drugs that lead to immunological activation [112] have been evaluated in clinical trials and are currently or will soon be receiving approval.